Successful commercialization of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular manufacturing, logistical and reimbursement hurdles that threaten commercial viability for any therapy with a less than spectacular clinical profile that truly changes the standard of care. This is particularly acute for autologous cell therapies where patients receive bespoke treatments manufactured from a sample of their own cells and where economies of scale, which play an important role in containing the production costs for small molecule and antibody therapeutics, are highly limited. Nevertheless, the promise of ‘game-changing’ efficacy, as exemplified by very high levels of complete responses in refractory haematological malignancies, has attracted capital investments on a vast scale, and the attendant pace of technology development provides promising indicators for future clinical and commercial success.
Skip Nav Destination
Article navigation
April 2016
-
Cover Image
Cover Image
Endoplasmic reticulumendosome contact sites. This pseudo-colored electron microscopy image shows the formation of inter-organelle membrane contact sites between late endosomes (magenta) and the endoplasmic reticulum (ER; green). This tethering results from the interaction between two ER-anchored proteins (VAP-A and VAP-B) and the late endosomeanchored protein STARD3NL. Mitochondria: brown; nucleus: blue. For further details see pp. 493-498. Image kindly provided by Fabien Alpy. - PDF Icon PDF LinkTable of Contents
Review Article|
April 11 2016
Commercialization of cellular immunotherapies for cancer
Anthony Walker;
Anthony Walker
1
*Alacrita LLP, 2 Royal College Steet, London NW1 0NH, UK
1To whom correspondence should be addressed (email awalker@alacrita.com).
Search for other works by this author on:
Robert Johnson
Robert Johnson
†Alacrita LLC, Cambridge Innovation Center, Kendall Square, Cambridge MA 02142, USA
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
February 04 2016
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© 2016 Authors; published by Portland Press Limited
2016
Biochem Soc Trans (2016) 44 (2): 329–332.
Article history
Received:
February 04 2016
Citation
Anthony Walker, Robert Johnson; Commercialization of cellular immunotherapies for cancer. Biochem Soc Trans 15 April 2016; 44 (2): 329–332. doi: https://doi.org/10.1042/BST20150240
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.